Literature DB >> 3346651

Single treatments with the antidepressant oxaprotiline and its (+) and (-) enantiomers increase behavioural responses to dopaminergic stimulation in the rat.

A Delini-Stula1, E Mogilnicka.   

Abstract

The effects of single doses of oxaprotiline and its (+)- and (-)-enantiomers (CGP 12 104 A and CGP 12 103 A, provisional generic name levoprotiline) on apomorphine- and amphetamine-induced stereotypies and amphetamine-induced hyperthermia were investigated in the rat. All 3 compounds enhanced and prolonged stereotyped responses to apomorphine and amphetamine at single doses of 10-30 mg/kg i.p. The most active appeared to be the (-)-enantiomer levoprotiline which is devoid of NA-uptake-inhibiting properties. Neither compound, however, potentiated amphetamine-induced hyperthermia, suggesting that enhanced behavioural effects are not due to the interference with metabolic degradation of amphetamine. The mechanism of the observed effect remains obscure, but in view of the reported clinical antidepressant action of levoprotiline these findings are interesting.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3346651     DOI: 10.1007/bf01245251

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  8 in total

1.  INFLUENCE OF IMPIRAMINE-LIKE COMPOUNDS AND CHLORPROMAZINE ON THE RESERPINE-HYPOTHERMIA IN MICE AND THE AMPHETAMINE-HYPERTHERMIA IN RATS.

Authors:  C MORPURGO; W THEOBALD
Journal:  Med Pharmacol Exp Int J Exp Med       Date:  1965

Review 2.  Hypotheses concerning the mechanism of action of antidepressant drugs.

Authors:  J Maj; E Przegalinski; E Mogilnicka
Journal:  Rev Physiol Biochem Pharmacol       Date:  1984       Impact factor: 5.545

3.  Repeated treatment with antidepressant drugs potentiates the locomotor response to (+)-amphetamine.

Authors:  J Maj; Z Rogóz; G Skuza; H Sowińska
Journal:  J Pharm Pharmacol       Date:  1984-02       Impact factor: 3.765

4.  Effects of thymoleptics on behavior associated with changes in brain dopamine. II. Modification and potentiation of apomorphine-induced stimulation of mice.

Authors:  L Molander; A Randrup
Journal:  Psychopharmacology (Berl)       Date:  1976-09-17       Impact factor: 4.530

5.  Stereospecificity of behavioural and biochemical responses to oxaprotiline--a new antidepressant.

Authors:  A Delini-Stula; K Hauser; P Baumann; H R Olpe; P Waldmeier; A Storni
Journal:  Adv Biochem Psychopharmacol       Date:  1982

6.  Oxaprotiline, a noradrenaline uptake inhibitor with an active and an inactive enantiomer.

Authors:  P C Waldmeier; P A Baumann; K Hauser; L Maitre; A Storni
Journal:  Biochem Pharmacol       Date:  1982-06-15       Impact factor: 5.858

7.  Repeated treatment with antidepressant drugs increases the behavioural response to apomorphine.

Authors:  J Maj; Z Rogóz; G Skuza; H Sowińska
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

8.  Modulation of dopamine-mediated behavioural responses by antidepressants: effects of single and repeated treatment.

Authors:  A Delini-Stula; A Vassout
Journal:  Eur J Pharmacol       Date:  1979-10-15       Impact factor: 4.432

  8 in total
  4 in total

1.  Some central pharmacological effects of (+)- and (-)-oxaprotiline.

Authors:  J Maj; Z Rogóź; G Skuza; H Sowińska
Journal:  J Neural Transm Gen Sect       Date:  1990

2.  Oxaprotiline enantiomers stimulate ACTH and corticosterone secretion in the rat.

Authors:  E Przegaliński; B Budziszewska; A Grochmal
Journal:  J Neural Transm Gen Sect       Date:  1991

3.  The effect of (+)- and (-)-oxaprotiline administered repeatedly on the dopamine system.

Authors:  J Maj; V Klimek; Z Rogóz; G Skuza; H Sowińska
Journal:  J Neural Transm Gen Sect       Date:  1991

4.  Effects of single and repeated treatment with antidepressants on apomorphine-induced yawning in the rat: the implication of alpha-1 adrenergic mechanisms in the D-2 receptor function.

Authors:  A Delini-Stula; C Hunn
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.